Healius (ASX:HLS) share price up 6% after tripling half year profits

Healius had a very strong half

| More on:
a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Healius shares are charging higher following the release of its half year results
  • Strong demand for PCR testing helped the company triple its profits
  • Healius increased its dividend by 54% to 10 cents per share

The Healius Ltd (ASX: HLS) share price has been among the best performers on the ASX 200 on Wednesday.

In afternoon trade, the healthcare company's shares are up 6% to $4.45 after the market responded positively to its half year results.

Healius share price higher amid stellar profit growth

  • Revenue up 43% to $1,339 million
  • Underlying earnings before interest and tax (EBIT) up 177% to $376.1 million
  • Underlying net profit after tax up 226% to $245.6 million
  • Fully franked interim dividend up 54% to 10 cents per share

What happened during the first half?

Healius had an incredibly positive half thanks largely to demand for COVID testing services. The company notes that it played a pivotal role in Australia's public health response to the Delta and Omicron outbreaks, with PCR testing the main driver of its 43% jump in revenue to $1,339 million.

This was supported by growth in non-COVID Pathology revenues, above market growth from its Victoria and Queensland imaging businesses, and revenue growth from its flagship day hospital, Westside Private.

Another positive was that its operating cash flow was strong and, normalised for exceptionally high volumes in the last two weeks of the year, EBITDA conversion was well over 90%.

Management highlights that its balance sheet remains conservatively geared and is positioned to reward shareholders, fund growth, and meet the sustaining capital needs of the business.

Management commentary

Healius' Managing Director and Chief Executive Officer, Dr Malcolm Parmenter, commented: "Following the huge surge in late December and early January, we have now returned to same-day turnaround times for PCR testing. We are expecting an on-going baseload of PCR testing for some time to come, as the clinical issues around this disease remain of concern, in particular for the more vulnerable within the population."

"Following the science, we are also investing in more efficiency initiatives in preparation for any new variants which may unfortunately coincide with increased influenza next winter. This includes investing to lower our cost per test and to handle a higher number of tests with the same level of staff," he added.

Looking ahead, Dr Parmenter expects the rest of its business to experience an acceleration in demand.

He explained: "With the country now opening up, all of our businesses are expecting an acceleration in demand for routine healthcare services, including a period of catch-up for the backlog in diagnosis and surgery. This is likely to be a strong driver for growth over the near-term, in particular our imaging and day hospitals businesses are well-placed to deliver on the return of elective surgery."

The chief executive also revealed that Healius intends to put its strong balance sheet to use.

He commented: "With the deleveraging of our balance sheet from the sale of Healius Primary Care and with the revenue we are receiving from COVID testing, as I have said before we have a real opportunity to invest in digital leading-edge applications to permanently change for the better how consumers access diagnostic healthcare in Australia. We're already on this path with our COVID digital initiatives and I am excited about what we can and will develop over the next few years."

No guidance has been given for the remainder of FY 2022.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Earnings Results

Man pointing at a blue rising share price graph.
Record Highs

This $23 billion ASX 200 stock just rocketed 11% to new all-time highs! Here's why

Investors in this ASX 200 financial share are bidding up the stock today. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Earnings Results

Guess which ASX All Ords stock just jumped 20%

Why are investors buying this tech stock on Wednesday? Let's find out.

Read more »

Female engineer at wind farm.
Earnings Results

Up 36% in a year, why is the AGL share price leaping higher again today?

ASX 200 investors are bidding up the AGL share price on Wednesday. But why?

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Earnings Results

CBA shares drop despite strong first-half profit result and dividend boost

Investors appear to have been wanting an even stronger result from Australia's largest bank.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Earnings Results

Evolution Mining share price storms higher on record-breaking result

This gold miner was in fine form during the first half. Here's what it reported.

Read more »

Business people discussing project on digital tablet.
Earnings Results

2 ASX 300 REITs reporting strong first-half profit growth

What did these property companies report this morning? Let's find out.

Read more »

Hand holding Australian dollar (AUD) bills, symbolising ex dividend day. Passive income.
Earnings Results

Suncorp share price jumps on strong result and $4.1b return to shareholders

This insurance giant is returning significant funds to shareholders after the sale of its banking operations.

Read more »

A woman wearing yellow smiles and drinks coffee while on laptop.
Earnings Results

CBA share price on watch after half-year profit beat

Australia's largest bank has delivered a strong result this morning. Here's what it reported.

Read more »